BioWorld

Feb. 1, 2007

Palatin Partners With AstraZenca In $310M Obesity Program Deal

In its second major collaboration involving melanocortin receptors, Palatin Technologies Inc. signed a potential $310 million deal with AstraZeneca plc to develop small-molecule compounds for obesity and other metabolic disorders. (BioWorld Today) Read More

Argenta Changeover Complete With Deal Worth Up To $500M

In Graft-Vs.-Host, Picking The Winners May Become Easier

HIV Microbicide Trials Stopped, Dropping Polydex's Stock Prices

YM Biosciences Suffers Setback With Stop Of Tesmilifene Trial

Repros Therapeutics Raising $36M On Positive Interim Data

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...